JP2018519797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519797A5 JP2018519797A5 JP2017557175A JP2017557175A JP2018519797A5 JP 2018519797 A5 JP2018519797 A5 JP 2018519797A5 JP 2017557175 A JP2017557175 A JP 2017557175A JP 2017557175 A JP2017557175 A JP 2017557175A JP 2018519797 A5 JP2018519797 A5 JP 2018519797A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- dsrna agent
- seq
- pharmaceutical composition
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 52
- 239000002773 nucleotide Substances 0.000 claims 44
- 239000003795 chemical substances by application Substances 0.000 claims 41
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 230000000692 anti-sense effect Effects 0.000 claims 11
- 206010019860 Hereditary angioedema Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 108091081021 Sense strand Proteins 0.000 claims 9
- 108010080865 Factor XII Proteins 0.000 claims 8
- 102000000429 Factor XII Human genes 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 230000004913 activation Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 230000037361 pathway Effects 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 101150072419 F12 gene Proteins 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000009467 reduction Effects 0.000 claims 3
- 229920002477 rna polymer Polymers 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- MPCAJMNYNOGXPB-UHFFFAOYSA-N 1,5-anhydrohexitol Chemical compound OCC1OCC(O)C(O)C1O MPCAJMNYNOGXPB-UHFFFAOYSA-N 0.000 claims 2
- 208000028185 Angioedema Diseases 0.000 claims 2
- 101800004538 Bradykinin Proteins 0.000 claims 2
- 208000007530 Essential hypertension Diseases 0.000 claims 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 2
- 102100035792 Kininogen-1 Human genes 0.000 claims 2
- 108700018490 Prekallikrein Deficiency Proteins 0.000 claims 2
- 230000008901 benefit Effects 0.000 claims 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 2
- ZDPUTNZENXVHJC-UHFFFAOYSA-N cumingianoside D Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(OP(O)(O)=O)C1O ZDPUTNZENXVHJC-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 230000002885 thrombogenetic effect Effects 0.000 claims 2
- 230000001732 thrombotic effect Effects 0.000 claims 2
- KBDWGFZSICOZSJ-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1H-pyrimidin-4-one Chemical group N1CNC=C(C1=O)C KBDWGFZSICOZSJ-UHFFFAOYSA-N 0.000 claims 1
- UOOOPKANIPLQPU-UHFFFAOYSA-N Cytidylic acid B Natural products O=C1N=C(N)C=CN1C1C(O)C(OP(O)(O)=O)C(CO)O1 UOOOPKANIPLQPU-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- NPRNBAPBGVERRF-ZOQUXTDFSA-N [(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl] dihydrogen phosphate Chemical compound CO[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 NPRNBAPBGVERRF-ZOQUXTDFSA-N 0.000 claims 1
- VXTNWQOOBHQEDS-IOSLPCCCSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl] dihydrogen phosphate Chemical compound CO[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VXTNWQOOBHQEDS-IOSLPCCCSA-N 0.000 claims 1
- PTESHFKYBQMNFR-FJGDRVTGSA-N [(2r,3r,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@](F)(O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 PTESHFKYBQMNFR-FJGDRVTGSA-N 0.000 claims 1
- KLVQSNKMLGBSHV-GIWSHQQXSA-N [(2r,3r,4s,5r)-5-(6-aminopurin-9-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@]1(O)F KLVQSNKMLGBSHV-GIWSHQQXSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000002657 hormone replacement therapy Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 230000008439 repair process Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020075777A JP7530204B2 (ja) | 2015-05-06 | 2020-04-22 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562157890P | 2015-05-06 | 2015-05-06 | |
| US62/157,890 | 2015-05-06 | ||
| US201562260887P | 2015-11-30 | 2015-11-30 | |
| US62/260,887 | 2015-11-30 | ||
| US201562266958P | 2015-12-14 | 2015-12-14 | |
| US62/266,958 | 2015-12-14 | ||
| PCT/US2016/030876 WO2016179342A2 (en) | 2015-05-06 | 2016-05-05 | Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020075777A Division JP7530204B2 (ja) | 2015-05-06 | 2020-04-22 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519797A JP2018519797A (ja) | 2018-07-26 |
| JP2018519797A5 true JP2018519797A5 (enExample) | 2019-06-06 |
| JP6695902B2 JP6695902B2 (ja) | 2020-05-20 |
Family
ID=55971215
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557175A Active JP6695902B2 (ja) | 2015-05-06 | 2016-05-05 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
| JP2020075777A Active JP7530204B2 (ja) | 2015-05-06 | 2020-04-22 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
| JP2022106599A Pending JP2022141707A (ja) | 2015-05-06 | 2022-06-30 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
| JP2023209185A Pending JP2024037849A (ja) | 2015-05-06 | 2023-12-12 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020075777A Active JP7530204B2 (ja) | 2015-05-06 | 2020-04-22 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
| JP2022106599A Pending JP2022141707A (ja) | 2015-05-06 | 2022-06-30 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
| JP2023209185A Pending JP2024037849A (ja) | 2015-05-06 | 2023-12-12 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20180100150A1 (enExample) |
| EP (1) | EP3292201A2 (enExample) |
| JP (4) | JP6695902B2 (enExample) |
| KR (2) | KR102827366B1 (enExample) |
| CN (2) | CN108271386B (enExample) |
| AU (2) | AU2016257996A1 (enExample) |
| BR (1) | BR112017021967A2 (enExample) |
| CA (1) | CA2984636A1 (enExample) |
| EA (1) | EA201792444A1 (enExample) |
| HK (1) | HK1249920A1 (enExample) |
| TW (4) | TWI887656B (enExample) |
| UY (2) | UY36671A (enExample) |
| WO (1) | WO2016179342A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113493789A (zh) * | 2015-03-17 | 2021-10-12 | 箭头药业股份有限公司 | 用于抑制因子xii的基因表达的组合物和方法 |
| TWI887656B (zh) | 2015-05-06 | 2025-06-21 | 美商阿尼拉製藥公司 | 第十二因子（哈格曼因子）（Ｆ１２）、激肽釋放素Ｂ、血漿（夫列契因子）１（ＫＬＫＢ１）及激肽原１（ＫＮＧ１）ｉＲＮＡ組成物及其使用方法 |
| EP3400301A4 (en) * | 2016-01-08 | 2019-11-27 | Alnylam Pharmaceuticals, Inc. | AGAINST FACTOR XII (HAGEMAN FACTOR) (F12) POLYNUCLEOTIDE AGENTS AND METHOD OF USE THEREOF |
| AU2018213379A1 (en) | 2017-01-30 | 2019-07-18 | Arrowhead Pharmaceuticals Inc. | Compositions and methods for inhibition of factor XII gene expression |
| BR112019021359A2 (pt) | 2017-04-11 | 2020-05-05 | Arbutus Biopharma Corporation | moléculas, composições, compostos, métodos para administrar um sirna, para preparar um composto e para tratar uma infecção, composto ou sal, conjugado de galnac e uso de um composto |
| US20200208150A1 (en) * | 2017-07-07 | 2020-07-02 | Alnylam Pharmaceuticals, Inc. | METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) |
| CN118291457A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105419A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| WO2019105435A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CA3087106A1 (en) | 2017-12-29 | 2019-07-04 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
| CN113330117B (zh) * | 2019-01-18 | 2024-05-28 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) * | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| EP3992290A4 (en) * | 2019-05-24 | 2023-11-15 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF |
| IL295280A (en) * | 2020-02-07 | 2022-10-01 | Intellia Therapeutics Inc | Preparations and methods for editing the kallikrein gene (klkb1) |
| WO2021195574A1 (en) * | 2020-03-27 | 2021-09-30 | Alnylam Pharmaceuticals, Inc. | Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| CN116670280A (zh) | 2020-12-18 | 2023-08-29 | Ionis 制药公司 | 用于调节因子xii的化合物和方法 |
| AU2022328347A1 (en) | 2021-08-13 | 2024-02-08 | Alnylam Pharmaceuticals, Inc. | Factor xii (f12) irna compositions and methods of use thereof |
| TW202346586A (zh) * | 2022-01-28 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 用於抑制前激肽釋放酶（pkk）蛋白表達的組合物和方法 |
| WO2024169577A1 (zh) * | 2023-02-14 | 2024-08-22 | 北京福元医药股份有限公司 | 用于抑制fxii基因表达的双链核糖核酸及其修饰物、缀合物和用途 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1861608A (en) | 1929-12-21 | 1932-06-07 | Emerson Electric Mfg Co | Fan and means for directing the air current therethrough |
| US1861108A (en) | 1930-01-24 | 1932-05-31 | Eugene O Brace | Integral clutch and transmission control |
| US3974808A (en) | 1975-07-02 | 1976-08-17 | Ford Motor Company | Air intake duct assembly |
| US4708708A (en) | 1982-12-06 | 1987-11-24 | International Paper Company | Method and apparatus for skiving and hemming |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| NL8901881A (nl) | 1989-07-20 | 1991-02-18 | Rockwool Grodan Bv | Drainagekoppelelement. |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| WO1993025673A1 (en) | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
| JPH07508410A (ja) | 1992-06-18 | 1995-09-21 | ジェンファーム インターナショナル インコーポレイテッド | 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法 |
| US5783701A (en) | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| EP0685457B1 (en) | 1993-02-19 | 1999-12-15 | Nippon Shinyaku Company, Limited | Glycerol derivative, device and pharmaceutical composition |
| US6054299A (en) | 1994-04-29 | 2000-04-25 | Conrad; Charles A. | Stem-loop cloning vector and method |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| DE69634084T2 (de) | 1995-06-07 | 2005-12-08 | Inex Pharmaceuticals Corp. | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
| US6034135A (en) | 1997-03-06 | 2000-03-07 | Promega Biosciences, Inc. | Dimeric cationic lipids |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| EE200000386A (et) | 1997-12-24 | 2001-12-17 | Vertex Pharmaceuticals Incorporated | Aspartüülproteaasi inhibiitorite eelravimid |
| WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| CA2345936A1 (en) | 1998-10-09 | 2000-04-20 | Ingene, Inc. | Production of ssdna in a cell |
| KR20010099682A (ko) | 1998-10-09 | 2001-11-09 | 추후보충 | 단일가닥 ｄｎａ의 효소 합성 |
| CO5261510A1 (es) | 1999-02-12 | 2003-03-31 | Vertex Pharma | Inhibidores de aspartil proteasa |
| IT1318539B1 (it) | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| SG2011071982A (en) * | 2001-05-25 | 2016-09-29 | Univ Duke | Modulators of pharmacological agents |
| US7063860B2 (en) | 2001-08-13 | 2006-06-20 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| KR20070085113A (ko) * | 2004-05-11 | 2007-08-27 | 가부시키가이샤 알파젠 | Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법 |
| NZ554214A (en) * | 2004-09-24 | 2009-10-30 | Alnylam Pharmaceuticals Inc | Rnai modulation of apob and uses thereof |
| EP1954822A1 (en) * | 2005-11-23 | 2008-08-13 | Georg Dewald | Detection and treatment of drug associated angioedema |
| US8178503B2 (en) * | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| US20070258952A1 (en) * | 2006-05-04 | 2007-11-08 | Baylor Research Institute | Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA |
| TW200804416A (en) * | 2006-06-19 | 2008-01-16 | Nautilus Technology Llc | Modified coagulation factor IX polypeptides and use thereof for treatment |
| AU2007275365A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
| WO2009053050A1 (en) * | 2007-10-22 | 2009-04-30 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| JP2012508569A (ja) * | 2008-11-17 | 2012-04-12 | エフ．ホフマン−ラ ロシュ アーゲー | 第ｖｉｉ因子遺伝子の発現を阻害するための組成物および方法 |
| SG10201912450XA (en) | 2009-06-10 | 2020-03-30 | Arbutus Biopharma Corp | Improved lipid formulation |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| US9512164B2 (en) | 2009-07-07 | 2016-12-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
| WO2012064758A2 (en) * | 2010-11-08 | 2012-05-18 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| WO2012170947A2 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| EP4092120A1 (en) * | 2011-06-21 | 2022-11-23 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (anglptl3) irna compositions and methods of use thereof |
| CN104105790A (zh) * | 2011-11-18 | 2014-10-15 | 阿尔尼拉姆医药品有限公司 | 修饰的RNAi试剂 |
| CN102600471A (zh) * | 2012-02-15 | 2012-07-25 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种败血症治疗的靶点 |
| US9574013B2 (en) * | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
| RU2649367C2 (ru) | 2013-01-30 | 2018-04-02 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты углевода и lna-олигонуклеотида |
| SG10201912286TA (en) * | 2013-03-14 | 2020-02-27 | Alnylam Pharmaceuticals Inc | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| RS57418B1 (sr) * | 2013-05-22 | 2018-09-28 | Alnylam Pharmaceuticals Inc | Serpina1 irnk sastavi i postupci njihove primene |
| EP3587578A1 (en) * | 2013-05-22 | 2020-01-01 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
| WO2016149020A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Research Corporation | Rna interference agents |
| CN113493789A (zh) | 2015-03-17 | 2021-10-12 | 箭头药业股份有限公司 | 用于抑制因子xii的基因表达的组合物和方法 |
| TWI887656B (zh) | 2015-05-06 | 2025-06-21 | 美商阿尼拉製藥公司 | 第十二因子（哈格曼因子）（Ｆ１２）、激肽釋放素Ｂ、血漿（夫列契因子）１（ＫＬＫＢ１）及激肽原１（ＫＮＧ１）ｉＲＮＡ組成物及其使用方法 |
| EP3400301A4 (en) | 2016-01-08 | 2019-11-27 | Alnylam Pharmaceuticals, Inc. | AGAINST FACTOR XII (HAGEMAN FACTOR) (F12) POLYNUCLEOTIDE AGENTS AND METHOD OF USE THEREOF |
| US11504391B1 (en) | 2016-11-23 | 2022-11-22 | Alnylam Pharmaceuticals, Inc. | Modified RNA agents with reduced off-target effect |
| AU2018213379A1 (en) | 2017-01-30 | 2019-07-18 | Arrowhead Pharmaceuticals Inc. | Compositions and methods for inhibition of factor XII gene expression |
| US20200208150A1 (en) | 2017-07-07 | 2020-07-02 | Alnylam Pharmaceuticals, Inc. | METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) |
| AU2022328347A1 (en) | 2021-08-13 | 2024-02-08 | Alnylam Pharmaceuticals, Inc. | Factor xii (f12) irna compositions and methods of use thereof |
-
2016
- 2016-05-05 TW TW112118563A patent/TWI887656B/zh active
- 2016-05-05 KR KR1020177033031A patent/KR102827366B1/ko active Active
- 2016-05-05 EP EP16723004.4A patent/EP3292201A2/en active Pending
- 2016-05-05 CN CN201680039784.6A patent/CN108271386B/zh active Active
- 2016-05-05 HK HK18109321.1A patent/HK1249920A1/zh active IP Right Revival
- 2016-05-05 CN CN202210790912.8A patent/CN115322991A/zh active Pending
- 2016-05-05 TW TW110113584A patent/TWI806034B/zh active
- 2016-05-05 EA EA201792444A patent/EA201792444A1/ru unknown
- 2016-05-05 AU AU2016257996A patent/AU2016257996A1/en not_active Abandoned
- 2016-05-05 BR BR112017021967A patent/BR112017021967A2/pt not_active Application Discontinuation
- 2016-05-05 TW TW114118710A patent/TW202536180A/zh unknown
- 2016-05-05 TW TW105113928A patent/TWI727948B/zh active
- 2016-05-05 JP JP2017557175A patent/JP6695902B2/ja active Active
- 2016-05-05 CA CA2984636A patent/CA2984636A1/en active Pending
- 2016-05-05 WO PCT/US2016/030876 patent/WO2016179342A2/en not_active Ceased
- 2016-05-05 KR KR1020257020838A patent/KR20250107273A/ko active Pending
- 2016-05-06 UY UY0001036671A patent/UY36671A/es active IP Right Grant
- 2016-05-06 UY UY0001040330A patent/UY40330A/es active IP Right Grant
-
2017
- 2017-11-01 US US15/800,517 patent/US20180100150A1/en not_active Abandoned
-
2019
- 2019-05-24 US US16/421,745 patent/US10934544B2/en active Active
-
2020
- 2020-04-22 JP JP2020075777A patent/JP7530204B2/ja active Active
- 2020-12-15 US US17/121,858 patent/US20210246447A1/en not_active Abandoned
-
2021
- 2021-10-28 AU AU2021258003A patent/AU2021258003A1/en not_active Abandoned
-
2022
- 2022-06-30 JP JP2022106599A patent/JP2022141707A/ja active Pending
-
2023
- 2023-07-05 US US18/218,155 patent/US12338439B2/en active Active
- 2023-12-12 JP JP2023209185A patent/JP2024037849A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519797A5 (enExample) | ||
| CN110268060B (zh) | α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法 | |
| CN111343994B (zh) | 用于抑制血管生成素-样3 (ANGPTL3)的表达的RNAi剂和组合物以及使用方法 | |
| AU2012322788B2 (en) | Micrornas in neurodegenerative disorders | |
| JP5066095B2 (ja) | 染色体ｄｎａに標的化されるオリゴマーによる遺伝子発現の調節 | |
| US20250270555A1 (en) | Organic compositions to treat beta-catenin-related diseases | |
| JP2017532038A5 (enExample) | ||
| RU2014147563A (ru) | КОМПОЗИЦИИ i-PHK ДЛЯ СЕРПИНА C1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| CN102149390A (zh) | 补体拮抗剂及其应用 | |
| JP2016518331A5 (enExample) | ||
| JP2009536827A5 (enExample) | ||
| CN108064313A (zh) | 用于抑制因子xii的基因表达的组合物和方法 | |
| JP2018516091A5 (enExample) | ||
| JP2015519047A5 (enExample) | ||
| JP2016506240A5 (enExample) | ||
| RU2014101627A (ru) | КОМПОЗИЦИИ иРНК ДЛЯ СХОДНОГО С АНГИОПОЭТИНОМ 3(ANGPTL3) БЕЛКА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| CN105008533A (zh) | 嵌合单链反义多核苷酸和双链反义试剂 | |
| JP2010532163A5 (enExample) | ||
| JP2009537153A5 (enExample) | ||
| TWI462741B (zh) | 使用微rna 195提供神經保護作用的方法 | |
| EP3665281A1 (en) | CONDITIONAL-siRNAS AND USES THEREOF IN TREATING CARDIAC HYPERTROPHY | |
| KR20240053627A (ko) | 안지오포이에틴-유사 3(angptl3) 단백질의 발현을 억제하기 위한 조성물 및 방법 | |
| JP2017510583A (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JPWO2021195307A5 (enExample) | ||
| JP2020537653A (ja) | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 |